Progen to license cancer R&D
Wednesday, 18 September, 2002
Drug developer Progen Industries is licensing development rights to a new patented cancer therapy from the University of New South Wales.
The agreement with the university's commercialisation arm, UniQuest, gives Progen exclusive world rights to technology covering a novel drug formulation and delivery mechanism with the potential to treat multiple cancers.
Progen is already in trials with its flagship anti-cancer drug, PI-88. It sees the newly-licensed therapy, labelled PI-166, as a complementary stablemate to PI-88 which will help fill Progen's drug pipeline.
PI-166 is currently in late-stage pre-clinical development and Progen will fund further R&D, including human trials, to provide further validation of the therapy.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
